Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

February 5, 2013

Primary Completion Date

August 13, 2017

Study Completion Date

August 13, 2017

Conditions

Rheumatoid ArthritisAnkylosing SpondylitisPsoriatic ArthritisCrohn´s DiseaseUlcerative ColitisPlaque Psoriasis

Interventions

DRUG

Adalimumab

Adalimumab administered by subcutaneous injection, via pre-filled syringe or autoinjector pen